RUNX1 and leukemia: Due to the difficulty in exploring oncofusion proteins as druggable targets, our findings serve to provide an innovative therapeutic strategy of targeting the non-histone function of EZH1 and lysine methylation for treatment of AML1-ETO leukemia.